Dr. Marisa S. Klein-gitelman, MD MPH
Pediatrics (Pediatric Rheumatology Physician)
2300 Childrens Plaza, #50
Chicago, IL 60614
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
Licensed in Illinois since 1994, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Rheumatology Physician primary
IL license 036089317 (first issued 1994; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $44,412 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $44,380 |
|---|---|
| GlaxoSmithKline, LLC. | $31.81 |
| Consulting Fee | $44,250 |
|---|---|
| Food and Beverage | $162 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Mar 7, 2025 | Consulting Fee | $24,500 |
| AstraZeneca Pharmaceuticals LP Sep 2, 2025 | Consulting Fee | $19,750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $85,429 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
AbbVie Inc. · Active, not recruiting · NCT03725007 - A longterm openlabel followup study of tofacitinib for treatment of juvenile idiopathic arthritis jia
Pfizer Inc. - M15-340 - A Study to Evaluate the Pharmacokinetics Safety and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
AbbVie Inc. - A Study to Evaluate the Pharmacokinetics Safety and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
AbbVie Inc. - Efficacy safety tolerability and pharmacokinetics of tofacitinib for treatment of systemic juvenile idiopathic arthritis sjia with active systemic features in children and adolescent subjects
Pfizer Inc. - An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT01357668
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.